Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Johnson and Johnson
Boehringer Ingelheim
McKinsey
AstraZeneca

Last Updated: December 10, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,889,740

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 8,889,740 protect, and when does it expire?

Patent 8,889,740 protects GOCOVRI and is included in one NDA.

This patent has four patent family members in three countries.

Summary for Patent: 8,889,740
Title:Composition and method for treating neurological disease
Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
Inventor(s): Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Jasper, GA), Porter; Seth (San Carlos, CA), Meyerson; Laurence R. (Las Vegas, NV), Burkoth; Timothy S. (Lake Bluff, IL)
Assignee: Adamas Pharmaceuticals, Inc. (Emeryville, CA)
Application Number:14/451,250
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,889,740
Patent Claim Types:
see list of patent claims
Composition; Compound; Device; Dosage form;

Drugs Protected by US Patent 8,889,740

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Adamas Pharma GOCOVRI amantadine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 208944-001 Aug 24, 2017 RX Yes No   Start Trial   Start Trial Y   Start Trial
Adamas Pharma GOCOVRI amantadine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 208944-002 Aug 24, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,889,740

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2588296   Start Trial
European Patent Office 1845968   Start Trial
European Patent Office 2623099   Start Trial
World Intellectual Property Organization (WIPO) 2006058236   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Dow
McKinsey
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.